Propanc Biopharma provides update on PRP clinical trial application and reverse common stock split.
M2 PHARMA-July 16, 2019-Propanc Biopharma provides update on PRP clinical trial application and reverse common stock split
(C)2019 M2 COMMUNICATIONS
Biopharmaceutical company Propanc Biopharma Inc (OTC:PPCBD) on Monday provided an update on the preparation of its anti-cancer lead product candidate PRP for clinical trial application submission as well as its reverse stock split.
The company stated that it intends to file its first clinical trial application of PRP in the second half of 2019 as well as launch its First-In-Human (FIH) study in advanced cancer patients for PRP during the first half of 2020. Approximately 80% of cancers are from solid tumors and metastasis is the main cause of patient death.
According to the company, PRP targets cancer stem cells resistant to standard treatments, that remain dormant for long periods then migrate to other organs, triggering explosive tumor growth and causing patient relapse. PRP is the mixture of two proenzymes (trypsinogen and chymotrypsinogen) from bovine pancreas. A synergistic ratio of these proenzymes inhibits growth of most tumor cells. Efficacy has been shown in pancreatic, kidney, breast, brain, prostate, lung, liver, uterine, and skin cancers .
At the opening of business on 24 June 2019, the company had completed its one for 500 reverse stock split of its common stock and the shares are now trading on the OTCQB on a post-split adjusted price. The trading symbol has temporarily changed to PPCBD and the trading symbol will revert to its original symbol PPCB.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 16, 2019|
|Previous Article:||Johnson & Johnson declares dividend of USD0.95 per share for Q3 2019.|
|Next Article:||EMMAC acquires 100% of Terra Verde with the oldest cannabis cultivation licence in Portugal.|